Active Ingredient(s): Denileukin Deftitox
FDA Approved: * February 5, 1999
Pharm Company: * SERAGEN
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Ontak Overview

Denileukin diftitox (trade name Ontak) was an antineoplastic agent, an engineered protein combining interleukin-2 and diphtheria toxin. Denileukin diftitox could bind to interleukin-2 receptors[1] and introduce the diphtheria toxin into cells that express those receptors, killing the cells. In some leukemias and lymphomas, malignant cells express these receptors, so denileukin diftitox can target these. In 1999, Ontak was approved by the U.S. Food and Drug Administration (F...

Read more Ontak Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Denileukin_diftitox

Recent Ontak Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Denileukin Deftitox
  • Injection: 150mcg/ml
  • Vial: 150ug/ml
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Ontak: (1 result)

Sorted by National Drug Code
  • 62856-603 Ontak 150 ug/ml Intravenous Injection, Solution by Eisai Inc.

Other drugs which contain Denileukin Deftitox or a similar ingredient: (1 result)